Upcoming Live Activities

Please join in on any of these upcoming live activities. Details regarding participation are found within the activity description.

Building on Progress, Marking New Milestones: The Present and Future of Immunotherapy in Locally Advanced and Early Lung Cancer

1.00 hr(s) | CME , NCPD , MOC , ABIM

Specialty: Immunotherapies , Lung Cancer

Therapeutic Area(s): Oncology , Immunology

Release Date: June 23, 2021

Expiration Date: June 23, 2021

Location: Live Webcast

The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs and rational combinations are starting to show promising activity as neoadjuvant and adjuvant therapies for patients with resectable stage I-III NSCLC as well. Optimal approaches are still being determined, and many questions and controversies remain, but it is essential for oncologists, thoracic surgeons, and other multidisciplinary specialists to work together to make these therapies available to patients with earlier stages of lung cancer. This PeerView Live web broadcast will provide essential updates on the evolving science supporting the use of ICIs in multimodal treatment of unresectable and resectable stage I-III NSCLC. Multidisciplinary perspectives on how to make the most of immunotherapies and rational combinations in the curative intent settings will be shared as well.

Gaining New Ground With Immunotherapy in the Management of Early and Advanced Gastrointestinal Cancers: Translating Progress Into Clinical Practice in Gastric, Esophageal, GEJ, and Colorectal Cancers

1.00 hr(s) | CME , MOC , ABIM

Specialty: Gastric Cancer , GI Cancers , GEJ cancer

Therapeutic Area(s): Oncology , Gastroenterology

Release Date: June 22, 2021

Expiration Date: June 22, 2021

Location: Live Webcast

In recent years, immune checkpoint inhibitors have demonstrated durable responses and prolonged survival benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biological rationale and latest practice-informing clinical trial evidence, along with practical guidance on incorporating these agents into clinical practice.

Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care

1.50 hr(s) | CME , MOC , ABIM

Specialty: Multiple Myeloma

Therapeutic Area(s): Hematology , Oncology

Release Date: June 17, 2021

Expiration Date: June 17, 2021

Location: Live Webcast

Recent changes in the multiple myeloma (MM) treatment landscape have occurred at “warp speed,” with multiple regulatory approvals making earlier breakthroughs appear modest by comparison. The validation of multiagent proteasome inhibitor and immunomodulatory platforms and the emergence of novel antibodies, cellular therapy, and targeted strategies have offered hematology-oncology professionals many more options to choose from when developing treatment plans. Modern management protocols can be individualized to achieve improved clinical outcomes across a range of treatment settings, from newly diagnosed to relapsed/refractory (including heavily pretreated) disease, as well as in transplant eligible and ineligible patients. This expert-led Seminars and Tumor Board event will make the “warp speed” changes in MM care comprehensible by focusing on the effects of newer therapeutics within specific disease settings. Each session will feature a dedicated Tumor Board component that will leverage the power of case-based learning to illustrate how professionals can apply evidence that can lead to improved patient outcomes in diverse MM patient populations and treatment settings. Don’t miss this exciting and informative event!

Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in Advanced and Early HR+ Breast Cancer Expert Perspectives on CDK4 and 6 Inhibitors and Other Novel Agents

1.50 hr(s) | CME , MOC , ABIM

Specialty: Breast Cancer

Therapeutic Area(s): Oncology

Release Date: June 17, 2021

Expiration Date: June 17, 2021

Location: Live Webcast

The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs), among many others. Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView Live web broadcast, developed in collaboration with top experts and in partnership with the Tigerlily Foundation, will focus on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs.

The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitor Advances Into Clinical Practice

1.50 hr(s) | CME , NCPD , MOC , ABIM

Specialty: Ovarian Cancer

Therapeutic Area(s): Oncology , Gynecology

Release Date: June 16, 2021

Expiration Date: June 16, 2021

Location: Live Webcast

The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational event that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView’s unique “Candid Conversations & Clinical Consults” format, this virtual event will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for the event, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life.

Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment

1.50 hr(s) | CME , NCPD , MOC , ABIM , ABPath , CC , ABS

Specialty: NSCLC

Therapeutic Area(s): Oncology

Release Date: June 16, 2021

Expiration Date: June 16, 2021

Location: Live Webcast

Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, there are currently seven molecular alterations that have FDA-approved matched therapies. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from these therapies, and thus, broad biomarker testing is essential to identify these patients, as is making the best rational therapies available to them. Many barriers to biomarker testing and appropriate biomarker-driven treatment exist, and there are also significant disparities in lung cancer clinical care and research, but effective steps can be taken to overcome them. An essential component of modern lung cancer management is patient education, which allows patients to become well-informed participants in their care and participate in shared decision-making with their multidisciplinary clinical teams.

Making the Most of Treatment Advances in SCLC: New Standards, Practicalities of Care, and Hope on the Horizon

1.50 hr(s) | CME , MOC , ABIM

Specialty: SCLC

Therapeutic Area(s): Oncology

Release Date: June 15, 2021

Expiration Date: June 15, 2021

Location: Live Webcast

Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and a unique myeloprotective agent has become available that can decrease the incidence of chemotherapy-induced myelosuppression in patients with SCLC. These developments have provided new hope to patients with SCLC, but they have also increased the urgency to diagnose and treat SCLC in a timely manner to ensure patients can derive benefits from these therapies.

Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics

1.50 hr(s) | CME , MOC , ABIM

Specialty: AML

Therapeutic Area(s): Hematology , Oncology

Release Date: June 15, 2021

Expiration Date: June 15, 2021

Location: Live Webcast

The increasing availability and use of novel therapeutics has eclipsed the once-standard and widespread use of conventional chemotherapy for patients with acute myeloid leukemia (AML). The growing arsenal of innovative agents—which now includes newer cytotoxic formulations, epigenetic and targeted agents, and novel antibodies—has also afforded clinicians the opportunity to develop treatment protocols designed to address unmet medical needs in many different AML populations.

Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease

1.00 hr(s) | CME , MOC , ABIM

Specialty: Melanoma

Therapeutic Area(s): Oncology , Dermatology

Release Date: June 15, 2021

Expiration Date: June 15, 2021

Location: Live Webcast

Immunotherapy has come to define the modern management model for malignant melanoma. Long-term evidence supports the use of PD-1 and CTLA-4 checkpoint inhibitors in unresectable, advanced/metastatic melanoma, while evidence from the adjuvant setting has confirmed immunotherapy’s role in resectable disease. Thus, immune checkpoint inhibitors and BRAF/MEK combinations for BRAF-mutant disease represent a platform on which to build further advances in melanoma care. New data suggest continued progress on several fronts, including novel PD-1–based combinations in advanced disease, neoadjuvant immunotherapy, and the potential of adjuvant immunotherapy in stage II melanoma.

Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity

1.50 hr(s) | CME , NCPD , MOC , ABIM

Specialty: HER2-positive Breast Cancer

Therapeutic Area(s): Oncology

Release Date: June 14, 2021

Expiration Date: June 14, 2021

Location: Live Webcast

The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time.

1 2
Copy link
Powered by Social Snap